GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indicati ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

SWIFT-1 and -2 showed depemokimab reduced exacerbation and hospitalisation rates as an add-on therapy for patients with asthma with type 2 inflammation In China, the submitted indications are for ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing schedule for these conditions. This could potentially transform treatment paradigms by reducing the ...